Background: Atrial fibrillation (AF) after rheumatic valve replacement is the most common arrhythmic complication. Previous studies reported angiotensin-II receptor blocker can prevent AF. This study aimed to assess the effect of a combination of irbesartan and amiodarone on the maintenance of sinus rhythm after cardioversion of AF in patients with post-rheumatic valve replacement in a randomized, controlled trial.
ersistent atrial fibrillation (AF) after rheumatic valve replacement surgery is the most frequent arrhythmia found in clinical practice. 1-3 After rheumatic mitral valve replacement surgery, morbidity of AF was 94%, and restoration of sinus rhythm without intervention accounted for only 6%. 4,5 Studies 1, 6 reported that 8.3% of early and 12.2% of late cardiac death resulted from AF, and the incidence of thrombosis and stroke in patients with AF was 17 times higher than those in patients without AF. So, it is very important to restore and maintain sinus rhythm after rheumatic valve replacement surgery. 7, 8 Cardiac structural remodeling, especially atrial fibrosis, was the key process of occurrence, development and maintenance of AF. 9 The development of a therapy directed against remodeling (or the confirmation that some available drugs might prevent this remodeling) could mark an important change in the management of patients with AF. 10 Studies performed on animals have shown the possible role of angiotensin-II receptor blocker for preventing atrial electrical remodeling. 11, 12 However, there is no controlled data on the value of angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers after cardioversion of persistent AF after rheumatic valve replacement surgery.
The purpose of this present prospective, randomized trial was to test the hypothesis that the recurrence of rheumatic valve-related AF after cardioversion could be reduced by irbesartan concomitant with amiodarone.
Methods
Patients with persistent AF after rheumatic valve replacement surgery referred to our arrhythmia unit for electrical cardioversion were prospectively included. All were outpatients in stable cardiac condition. Patients had AF continuously for >7 days. A complete study was performed to detect structural heart disease. This study protocol has been approved by the medical ethics committee and is consistent with the spirit of the Declaration of Helsinki. All selected patients have signed JI Q et al.
an informed consent approved by the ethics committee.
Inclusion and Exclusion Criteria
Patients had to have an episode of AF lasting >7 days. Electrocardiographic confirmation of persistent AF was required at least 3 times. No patient with paroxysmal or self-terminating AF episodes was included. All patients underwent valve replacement surgery over 3 months with a past history of rheumatic heart disease. All patients were >18 years of age.
Patients were excluded from this study on the basis of the following criteria: the size of left atrium was >60 mm; thrombi in the left atrium; time lapse between surgery and study over 20 years; myocardial infarction during the previous 6 months; unstable angina; NYHA heart failure class IV; cardiac surgery during the previous 3 months; significant thyroid, pulmonary, or hepatic disease and/or contraindications to treatment with amiodarone; significant impairment of renal function; pregnant or fertile female; QT >480 ms in the absence of bundle-branch block; bradycardia <50 beats/min while the patient was awake; sick sinus syndrome; or any other medical condition that, in the opinion of the investigators, could make the patient inappropriate for the study.
Methods
All selected patients were divided randomly into an irbesartan plus amiodarone group and an amiodarone group through a computer-generated randomization sequence. The randomization assignment for each patient was kept in a sealed envelope, which was opened by a trial investigator at the time of patient enrollment. Patients in the amiodarone group received a continuous amiodarone (Sanofi-Aventis, Paris, France) infusion at a dose of 600 mg/d for 10 days with concomitant oral amiodarone overlap for 3 days (400 mg amiodarone orally twice a day) before direct-current cardioversion. Patients in the irbesartan plus amiodarone group received an oral administration of irbesartan (Sanofi-Aventis, Paris, France) of 150 mg/d, which could be increased to 300 mg/d in hypertensive patients, and received amiodarone at the same dose as those patients in the amiodarone group for 10 days. If normal sinus rhythm was not established within 10 days of medical treatment, then electrical cardioversion (synchronized directcurrent cardioversion) would have been performed. Synchronized direct-current cardioversion was performed during the morning hours with the patient in the fasting state. After the administration of 1.5 mg/kg intravenous propofol, the patients were shocked with R wave-synchronized monophasic discharges (Physio-control Lifepak 9B), beginning with 200J and ranging up to 360J (anterolateral approach). If unsuccessful, 2 shocks of 200 and 360J were applied in the anteroposterior direction, followed by 2 anteroposterior biphasic shocks (200-360J) (Medtronic Physio-control Lifepak 12). Successful cardioversion was defined as sinus rhythm recovery lasting for at least 2 min after the shock. Those patients who did not revert to sinus rhythm after electrical cardioversion were considered to have finished the follow up. After electrical cardioversion, all the patients were maintained on a daily dose of 200 mg of amiodarone. Patients receiving irbesartan were continued on the same dose of irbesartan initiated before cardioversion. However, the dose of irbesartan was increased in those patients who experienced high blood pressure.
During the surveillance for recurrence of AF, 2 cardiologists from the arrhythmia unit examined the patients. Patients were examined weekly during the first month, then at 3, 6, 9 and 12 months, and at any time any patient complained of palpitations or any other symptoms. The cardiologist who assessed the patient was unaware of the patient's group assignment. A 24-h holter recording was performed at 1, 3, 6, 9 and 12 months, and at any time any patient had such symptoms as palpitations, dizziness, or syncope. Echocardiography was also performed during each visit for assessment. The trial was to be interrupted on basis of the following: QT >550 ms or over 25% of baseline; ventricular rate <50 beats/min and blood pressure <90/60 mmHg; significant impairment of lung function; hypothyroidism or hyperthyroidism; adverse reactions of the digestive system or continuous elevated liver enzymes; continuous elevated serum creatinine.
The primary end-point of the trial was the time when a first electrocardiographically confirmed recurrence of AF or atrial flutter lasting for >10 min occurred. The secondary endpoints were the number of times electrical shocks were given, the total energy given for the electrical cardioversion and changes in the size of the left atrium. The beginning of the follow up was considered to be the day of the scheduled electrical cardioversion (just after the electrical cardioversion was performed or the pharmacological cardioversion documented). Failure time was set at 0 days for patients who failed to cardioversion on this day.
Statistical Analysis
The sample size calculations are based on an estimated efficacy at 1 year of 70% for amiodarone plus irbesartan combination and 40% for only amiodarone. With an α level of 0.05 and a test power of 0.80, the resulting sample size was 40 patients for each treatment group. A risk of loss of patients to follow up of 1-5% was assumed.
Data are expressed as mean ± standard deviation for continuous variables, and frequencies were measured for categorical variables. The unpaired t-test or t'-test according to the homogeneity test for variance was used to compare measurement data and Fisher's exact test was used to compare enumeration data. The time of first AF recurrence was analyzed with the Kaplan-Meier method and compared with the log-rank test. The hazard ratio and its confidence intervals (CI) were estimated using the Cox regression model. We analyzed the recurrence of AF using Cox proportional hazards regression to control for potentially confounding factors. The factors were selected on the basis of a change in the relative risk of ≥20%. All P values <0.05 were considered to be statistically significant. Statistical analysis was performed using the SPSS 13.0 statistical software package.
Results

Study Population
From January 2006 to December 2008, a total of 95 consecutive patients who met the inclusion criteria were randomly divided into an amiodarone group (n=48) and an irbesartan plus amiodarone group (n=47). Seven patients were excluded (the size of the left atrium was >60 mm in 4 patients, 1 patient had NYHA class IV and 2 patients had chronic renal dysfunction), 3 patients were withdrawn from analysis because of the withdrawal of their consent for electrical cardioversion, and finally 85 patients (43 patients in the irbesartan plus amiodarone group and 42 patients in the amiodarone group) were analyzed.
Baseline Characteristics
The baseline demographic and clinical characteristics as well as the baseline concomitant drugs use in the 2 groups are shown in Table 1 . There were no differences in the duration Irbesartan Plus Amiodarone in Rheumatic AF of persistent AF before randomization between the 2 groups (2.7±1.4 years in the irbesartan plus amiodarone group vs 3.2±2.0 years in the amiodarone group, P=0.18). Blood pressure values were not significantly different in patients treated with irbesartan as opposed to those without (the irbesartan plus amiodarone group: 114±16 systolic and 76±8 mmHg diastolic; the amiodarone group: 115±15 systolic and 77±9 mmHg diastolic; P=0.77 and 0.59, respectively). According to Table 1 , demographic and clinical variables as well as the baseline concomitant drug use were similar in both groups. Although all selected patients were assigned randomly to 1 of the groups, time lapse between surgery and the study in the amiodarone group was longer than that in the irbesartan plus amiodarone group (4.1±1.8 years vs 3.5±1.2 years). However, the difference was not statistically significant (P=0.07).
Pharmacological Conversion After Randomization
Before the scheduled electrical cardioversion, pharmacological conversion was documented in 7 patients (8.2%), of whom 5 patients (11.6%) were in the irbesartan plus amiodarone group and 2 (4.8%) were in the amiodarone group. Table 2 , synchronized direct-current cardioversion was performed in 78 patients and was successful in 68 patients (87.2%). Unsuccessful electrical cardioversion was observed in 7 patients pretreated with only amiodarone, and in 3 patients pretreated with irbesartan plus amiodarone (17.5% vs 7.9%, P=0.31). Patients who had successful electrical cardioversion therapy in the amiodarone group had a mean body mass index (BMI) of 23.3±2.9, required 1.8±0.8 shocks, and had a required total energy of 396±226 J. Patients who had successful electrical cardioversion therapy in the irbesartan plus amiodarone group had a similar BMI (23.5± 3.0 vs 23.3±2.9, P=0.78) but tended to have had a lower number of shocks and a lower total energy given for the electrical cardioversion (1.4±0.6 shocks vs 1.8±0.8 shocks, P=0.02; 288±167 J vs 396±226 J, P=0.03, respectively). Patients in the irbesartan plus amiodarone group had a higher number of successful cardioversions after only 1 shock (P=0.04).
Electrical Cardioversion As shown in
Four patients were observed with severe sinus bradycardia immediately after synchronized direct-current cardioversion, and their heart rate was restored to over 60 beats/min after having received atropine. Frequent atrial tachycardia occurred in 14 patients. No sinus arrest, cardiac arrest, severe ventricular arrhythmia or thrombi events occurred.
Recurrence of AF During the 1-Year Follow-up Period
During the 1-year follow-up period, 38 patients had a recurrence of AF. The recurrence rate in the irbesartan plus JI Q et al.
amiodarone group was significantly lower than that in the amiodarone group (30.2% vs 59.5%, P=0.01). As shown in Figure 1 , Kaplan-Meier curves confirmed a significantly better AF-free survival in the irbesartan plus amiodarone group (Log-rank χ2 =7.466, P=0.006).
Cox regression revealed that the use of the irbesartan and the size of the left atrium were 2 significant variables related to the maintenance of sinus rhythm after cardioversion. After the Cox proportional model was used, correcting for those variables that could influence the result (eg, the presence of diabetes, time lapse between surgery and study, or duration of AF), the hazard ratio for recurrence in patients treated with irbesartan was 0.43 (95%CI 0.25-0.87; P=0.018), reflecting a 57.4% reduction in the risk of recurrence of AF. And the hazard ratio for recurrence in patients with an increased left atrium diameter was 1.54 (95%CI 1.12-3.24; P=0.005).
Size of the Left Atrium
Echocardiography was performed in all patients at 3, 6, 9 and 12 months after cardioversion. The size of the left atrium gradually increased in the 2 groups during the 12-month follow-up period (Figure 2) . The size of the left atrium in the irbesartan plus amiodarone group increased from 46.6± 4.8 mm before cardioversion to 48.8±5.8 mm at the 12-month follow-up visit. However, there was no significant difference (P=0.06). The size of the left atrium in the amiodarone group increased significantly from 46.3±5.0 mm before cardioversion to 52.3±6.9 mm at the 12-month follow-up visit (P< 0.0001). At the 3-and 6-month follow-up visit, sizes of the left atrium in the irbesartan plus amiodarone group were smaller than those in the amiodarone group, but there was no significant differences between the 2 groups (P=0.36, P= 0.08, respectively). At the 9-and 12-month follow-up visit, sizes of the left atrium in the irbesartan plus amiodarone group were significantly smaller than those in the amiodarone group, respectively (47.6±6.2 vs 50.8±6.3 mm, P=0.02; 48.8±5.8 vs 52.3±6.9 mm, P=0.01, respectively). HR, heart rate. Other abbreviations see in Table 1 .
Irbesartan Plus Amiodarone in Rheumatic AF
Adverse Events During the 1-Year Follow-up Period
In total, adverse events requiring the discontinuation of amiodarone were not observed during follow up. Four patients (2 patients in the irbesartan plus amiodarone group and 2 in the amiodarone group) had bradycardia (heart rate:
50-60 beats/min), but amiodarone treatment was not interrupted as no patient complained of discomfort. No ventricular tachycardia, ventricular fibrillation, or third degree atrioventricular block occurred. No one required permanent pacemaker implantation. Temporary blood pressure depres- JI Q et al.
sion was observed in 4 patients during the early days after cardioversion; it gradually returned to the normal range. As shown in Figure 3 , there was no significant reduction in both systolic blood pressure and diastolic blood pressure in the 2 groups during the 12-month follow-up period. The left ventricular ejection fraction (LVEF) did not significantly decrease after administration of irbesartan plus amiodarone (58.5±7.9% baseline vs 57.9±8.3% at the 12-month followup visit, P=0.73). Whether they were the baseline or at the 12-month follow-up visit, LVEF values in the irbesartan plus amiodarone group were the same as that in the amiodarone group (baseline: 58.5±7.9% vs 58.1±6.5%, P=0.80; at the 12-month follow-up visit: 57.9±8.3% vs 57.5±7.9%, P=0.82).
No case of pulmonary toxicity, pulmonary thromboembolism, or thyroid dysfunction was observed. Ten patients (6 patients in the irbesartan plus amiodarone group and 4 in the amiodarone group) complained of gastrointestinal discomfort during the early days after cardioversion. Gastrointestinal ulcers were not observed during follow up. Nine patients had mild dermatologic events (photosensitivity). Neither liver dysfunction nor renal insufficiency was observed. No patient underwent any non-cardiac surgery. No deaths occurred during follow up.
Discussion
The incidence of AF recurrence after rheumatic valvular replacement used to be 25-50% at 1 month after cardioversion, and hit the 70-90% mark at 1 year after cardioversion. 4-6 After cardioversion, anti-arrhythmic drugs were often introduced to prevent the recurrence of AF. In the APAF trial, sotalol reduced the risk of developing AF over 1 year by 6%, and amiodarone reduced the risk of developing AF over 1 year by nearly 50%. 13 In this study, the recurrence rate after cardioversion of AF after rheumatic valve replacement surgery hit 59.5% by treatment with only amiodarone for 1 year. Obviously, the effect of the antiarrhythmic drugs on AF was not completely satisfactory. 14, 15 Angiotensin-II receptor blockers, on the basis of their favorable effects on cardiovascular fibrosis and apoptosis, were given more and more attention. Several studies 16, 17 showed angiotensin-II receptor blockers could reduce the recurrence of AF in patients with hypertension and myocardial infarction. In this study, the maintenance of sinus rhythm by treatment with irbesartan plus amiodarone for 1 year was 69.8%, which was significantly higher than by treatment with only amiodarone (69.8% vs 40.5%, P=0.01). Cox regression showed that the hazard ratio for a recurrence in patients treated with irbesartan plus amiodarone was "0.43", reflecting a 57.4% reduction in the risk of AF recurrence. This study proved irbesartan could reduce the recurrence of AF after rheumatic valve replacement surgery and could maintain sinus rhythm. The combination of irbesartan and amiodarone led neither to severe low blood pressure nor bradycardia nor atrioventricular block, etc. The combination of irbesartan and amiodarone shared similar rates among adverse events as compared to only amiodarone during the 1-year follow-up visit. So, this study was in favor of the safety and tolerability of the combination of irbesartan and amiodarone.
The renin-angiotensin system (RAS) plays a key role in the occurrence and development of AF. 18,19 Angiotensin-II, the main active ingredient of RAS, mediated cardiac structural remodeling: advanced proliferation of fibroblasts, promoted myocardial interstitial collagen deposition through up-regulating extracellular signal-regulated kinase, inhibited the decomposition of collagen through down-regulating the activity of collagen matrix metalloproteinase-1, regulated transforming growth factor-β1, fibroblast growth factor, epidermal growth factor and other factors involved in the process of atrial fibrosis, and so on. 19,20 Cardiac structural remodeling, especially atrial fibrosis, was the most important process of occurrence, development and maintenance of AF. 20 Angiotensin-II receptor blocker blocked signal transduction pathways related with atrial fibrosis through the intervention of RAS, and then blocked the process of atrial structural remodeling, thereby prevented the incidence or reduced the recurrence of AF. Angiotensin-II receptor blocker has proved to be effective for preventing AF. 19, 21 In this study, Cox regression revealed that an increased size of the left atrium was one high risk factor for the maintenance of sinus rhythm after cardioversion. The hazard ratio for AF recurrence in patients with an increased size of the left atrium diameter was "1.54", which meant as the size of the left atrium diameter increased by 1 mm, the risk of AF recurrence after cardioversion increased 1.54 times. So, this study was in favor of atrial structural remodeling playing an important role in the occurrence, development and maintenance of AF.
In patients with rheumatic heart disease, a long period of rheumatic activity led to progressive myocardial tissue fibrosis, which contributed to intra-atrial conduction block, thereby increasing the likelihood of AF and increasing the difficulty of treatment. 22 In this study, the maintenance of sinus rhythm was only 55.3%, which was lower than that in other reports. 16,17 Although valve replacement surgery was performed in all patients in this study, a larger size of the left atrium before cardioversion and progressive enlargement of the left atrium during the 1-year follow-up period were observed, which might be the main reason for the low maintenance of sinus rhythm. The size of the left atrium at the 12-month follow-up visit was slightly larger than that of baseline data in the irbesartan plus amiodarone group, but no statistically significant difference was found. However, the size of the left atrium significantly increased at the 12-month follow-up visit compared to the baseline data of the amiodarone group. And the size of the left atrium in the irbesartan plus amiodarone group was significantly lower than that in the amiodarone group at the 12-month follow-up visit. This study was in favor of irbesartan decreasing the recurrence of AF through suppression of atrial structural remodeling. Also, persistent AF after valve replacement surgery should undergo electrical cardioversion as soon as possible before the size of the left atrium increases significantly.
In addition, patients who had successful cardioversion therapy in the irbesartan plus amiodarone group had a trend to a lower number of shocks and a lower total energy given for the electrical cardioversion, and had a higher number of successful cardioversions after only one shock in this study, which meant pretreatment with irbesartan might be helpful in the electrical cardioversion of AF after rheumatic valve replacement surgery. This might be related to irbesartan alleviating atrial electrical remodeling. 12, 16 This study did not include high-risk patients with persistent AF after rheumatic valve replacement. We cannot definitely exclude the fact that, between scheduled follow-up visits, some of the patients had asymptomatic recurrences of AF that converted spontaneously. However, patients with paroxysmal and self-terminating AF were not included in the present study. Many hypertensive drugs can stimulate angiotensin secretion. Whereas diuretics invariably cause a rise in plasma rennin activity, the β-blockers depress rennin Irbesartan Plus Amiodarone in Rheumatic AF activity. However, the percentage of patients using diuretics and β-blockers was similar in both groups, respectively. Although combination therapy was superior to amiodarone alone, monotherapy with irbesartan alone was not tested. The success of irbesartan might differ, depending on the degree of atrial remodeling before cardioversion. In addition, the improved outcome still needs to be investigated in more patients with persistent AF after rheumatic valve replacement.
In conclusion, in patients with post-rheumatic valve replacement, the combination of amiodarone and irbesartan demonstrated a lower rate of AF recurrence after cardioversion than amiodarone alone, which might be due to preventing the atrial remodeling.
